Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
7.24
-0.47 (-6.10%)
At close: Dec 5, 2025, 4:00 PM EST
7.14
-0.10 (-1.38%)
After-hours: Dec 5, 2025, 7:37 PM EST

Moleculin Biotech Stock Forecast

MBRX's stock price has decreased by -88.46% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 4 professional analysts, the 12-month price target for Moleculin Biotech stock ranges from a low of $100 to a high of $200. The average analyst price target of $125 forecasts a 1,626.52% increase in the stock price over the next year.

Price Target: $125.00 (+1,626.52%)
Analyst Consensus: Strong Buy
Target Low Average Median High
Price $100 $125 $100 $200
Change +1281.2% +1626.5% +1281.2% +2662.4%
* Price targets were last updated on Sep 10, 2025.

Analyst Ratings

The average analyst rating for Moleculin Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Jul '25Aug '25Sep '25Oct '25Nov '25Dec '25
Strong Buy 344444
Buy 000000
Hold 000000
Sell 000000
Strong Sell 000000
Total 344444

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$100
Strong Buy Reiterates $100 +1,281.22% Sep 10, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$100
Strong Buy Reiterates $100 +1,281.22% Aug 27, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Reiterates
$100
Strong Buy Reiterates $100 +1,281.22% Jun 18, 2025
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Initiates
$100
Strong Buy Initiates $100 +1,281.22% Jun 9, 2025
Maxim Group
Maxim Group
Strong Buy
Upgrades
$100
Strong Buy Upgrades $100 +1,281.22% Mar 25, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-21.68
from -158.02
EPS Next Year
-17.47
from -21.68
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026
Revenue
-------
Revenue Growth
-------
EPS
-661.02-221.77-380.52-376.71-158.02-21.68-17.47
EPS Growth
-------
Forward PE
-------
No. Analysts
-----55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202520262027202820292030
High n/a n/a
Avg n/a n/a
Low n/a n/a

Revenue Growth

Revenue Growth 202520262027202820292030
High - -
Avg - -
Low - -

EPS Forecast

EPS 20252026202720282029
High -22.31 -13.65
Avg -21.68 -17.47
Low -20.83 -20.83

EPS Growth

EPS Growth 20252026202720282029
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.